CNBX Pharmaceuticals

CNBX Pharmaceuticals is a global leader in the development of cancer and cancer-related cannabinoid-molecule-based therapeutic formulations and medicines. Since its establishment in 2012, CNBX Pharmaceuticals has been pioneering research on the antitumor effects of cannabinoid formulations on cancer, with a focus on colorectal cancer. Their flagship drug candidate, CNBX RCC-33, is the world's first cannabinoid-based antitumor drug candidate for the treatment of colorectal cancer.

This novel and proprietary formulation has shown promising results, with yellow markers indicating dead cancer cells after just 24 hours. CNBX Pharmaceuticals conducts cutting-edge research and development in their state-of-the-art in-house drug discovery facilities. Using proprietary High Throughput Screening (HTS) technology and advanced bioinformatics, they are able to identify and develop drug candidates for various types of cancer, including colorectal cancer, pre-cancerous polyps, melanoma, breast cancer, and prostate cancer.

With a dedicated team of leaders and a strategic approach, CNBX Pharmaceuticals is committed to advancing the field of cannabinoid-based antitumor research and providing innovative solutions for cancer treatment. To stay updated on their groundbreaking work, visit their media newsroom or contact them directly